Register

Registration

Note : After Answered of Questionnaires / Survey Please Close it.
.

Dr Lal Pathlabs Ltd . Large Cap

BSE: 539524 | NSE: LALPATHLAB
Healthcare
Live
20/04/2021 4:00:00 PM
2903.20 -95.55   (-3.19%)
BSE: price shown with 5 mins delayed.
Prev. Close 2998.75
Open Price 2931.00
Volume Traded 45398.00

Fundamentals

Mar'11 Mar'12 Mar'13 Mar'14 Mar'15 Mar'16 Mar'17 Mar'18 Mar'19 Mar'20
Ajusted EPS(Rs.) 790.45 1219.14 1582.09 144.25 16.9 16.11 18.73 20.61 24.05 27.31
Net Sales (Rs. Cr.) 237.27 342.21 451.66 557.95 659.59 791.32 912.38 1056.92 1203.42 1330.36
Adjusted Net Profit 29.64 45.28 55.93 80.81 96.38 133.19 155.78 170.99 200.42 227.48
Book Value/ Share(Rs.) 2688 3407.99 4780.6 381.64 57.56 61.28 71.69 98.05 116.78 126.81
Cash Flow 1.04 3.53 9.33 -1.54 7.52 -4.59 1.94 37.30 63.54 67.33
Debt to Cash Flow from Operations 0.47 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
RONW 29.41 39.80 38.65 42.40 35.57 32.42 28.22 24.83 23.13 23.01
ROCE % 37.82 55.73 52.77 55.32 45.61 45.08 41.88 37.49 34.59 31.44
Net Operating Profit Margin % 24.58 25.21 22.27 26.25 25.46 28.94 28.97 27.85 28.15 28.81
Net Profit Margin % 12.45 13.20 12.32 14.38 14.62 16.84 17.05 16.25 16.66 17.11
Debt / Equity 0.21 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield % 0.00 0.00 0.00 0.00 0.00 0.27 0.15 0.14 0.37 0.40
Mar'11 Mar'12 Mar'13 Mar'14 Mar'15 Mar'16 Mar'17 Mar'18 Mar'19 Mar'20
Ajusted EPS(Rs.) 757.4 1095.17 1380.24 132.49 16.05 15.21 18.36 20.19 23.45 26.78
Net Sales (Rs. Cr.) 224.66 319.13 421.17 540.79 636.61 765.4 881.88 1024.04 1164.9 1273.6
Adjusted Net Profit 28.51 41.09 49.06 74.50 91.70 125.69 152.74 168.39 195.40 223.06
Book Value/ Share(Rs.) 2680.96 3290.37 4476.51 352.42 53.56 57.88 70.6 96.69 115.02 124.83
Cash Flow 0.39 3.48 8.55 0.02 8.96 -4.90 0.59 36.41 61.42 65.30
Debt to Cash Flow from Operations 0.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
RONW 27.64 36.49 35.55 41.91 36.40 32.58 28.62 24.69 22.89 22.92
ROCE % 40.02 52.20 48.95 55.26 47.18 45.68 42.31 37.24 34.15 31.14
Net Operating Profit Margin % 24.45 24.71 21.14 26.40 26.25 29.23 29.22 28.01 28.20 29.11
Net Profit Margin % 12.65 12.85 11.61 13.67 14.41 16.43 17.29 16.43 16.78 17.52
Debt / Equity 0.11 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield % 0.00 0.00 0.00 0.00 0.00 0.27 0.35 0.43 0.37 0.40

Year on Year Growth Rate (%)

Ajusted EPS Sales Adjusted Net Profit

Latest Financials

Standalone Consolidated
TTM EPS (Rs) 28.4 28.88
TTM Sales (Rs. Cr.) 1373.9 1452
BVPS (Rs.) 136.20 138.77
Reserves (Rs. Cr.) 1051.8 1073.2
P/BV 21.32 20.92
PE 105.59 103.83483
From the Market
52 Week High / Low (Rs) 3398.95/1445.5
All Time High / Low (Rs) 1278.55/696.5
Volume Traded 45398
Market Cap (Rs. Cr.) 24993.04
Equity (Rs. Cr.) 83.344877
Face Value (Rs) 10
Industry PE 0

Quarterly Results

Mar'2020 Jun'2020 Sep'2020 Dec'2020
Net Sales (Cr) 287.50 255.00 404.30 427.10
Adjusted EPS (Rs) 4.24 3.46 9.59 11.13
Net Profit Margin % 12.28 11.29 19.76 21.70
Mar'2020 Jun'2020 Sep'2020 Dec'2020
Net Sales (Cr) 301.70 266.00 431.90 452.40
Adjusted EPS (Rs) 3.90 3.41 10.24 11.34
Net Profit Margin % 10.77 10.68 19.75 20.89

Quarterly Growth Rate (%)

Ajusted EPS Sales Net Profit Margin

Peers Data

Name Current Price(Rs) Market Cap. (Rs. cr.) Net Profit(Rs. cr.) Sales Growth(%)
Shree Pacetronix Ltd 0 4.17 0.28 -37.94
Medinova Diagnostic Services Ltd 26.35 25.05 0 64.36
Transgene Biotek Ltd 5.09 39.32 -10.96 0.00
Fortis Malar Hospitals Ltd 60.35 112.83 -9.06 -55.83
Poly Medicure Ltd 888.5 8465.77 92.38 -15.68
Dr Lal Pathlabs Ltd 2903.2 24993.04 223.18 -14.70
Apollo Hospitals Enterprise Ltd 3272.85 45371.97 470.3 -31.15

Technical

Sector

23387.09 280.75   (1.22%)

Index

47705.80 -243.62   (-0.51%)
9 Days Avg
Span A Span B 52 Week TenKan-Sen Kijun-Sen ChiKou-Sen
9 Days Avg

Score

Kindly subscribe to get access

Research Analytical

Kindly subscribe to get access

News

2021/04/09 08:53

Dr Lal Pathlabs grants 1.14 lakh stock options under ESOP

Dr Lal Pathlabs has granted 1,14,844 Restricted Stock Unit options (Options) under the Dr. Lal Pathlabs Employee Restricted Stock Unit Plan 2016.

Powered by Capital Market - Live News

About Company

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Dr. Lal PathLabs has built a national, 'hub and spoke' network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 191 other clinical laboratories, 2153 patient service centers and 5,624 pickup points as of March 31, 2018. Its customers include individual patients, hospitals and other healthcare providers and corporate customers. The catalogue of services includes 1,110 test panels, 2,028 pathology tests and 1,561 radiology and cardiology tests.Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company 'Dr Lal Pathlabs Pvt Ltd'The Company was incorporated as Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. The Company was converted into a public company pursuant to a special resolution of the shareholders of our Company at an EGM held on August 7, 2015. Consequently, the name of our Company was changed to Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015.The Board of Directors of Dr. Lal PathLabs at its meeting held on 27 May 2016 approved acquisition of M/s Delta Ria and Pathology Private Limited. The Board also approved the acquisition of additional 10% stake each in Dr. Lal PathLabs' subsidiaries M/s Paliwal Diagnostics Private Limited (PDPL) and Paliwal Medicare Private Limited. The Board of Directors of Dr. Lal PathLabs at its meeting held on 12 May 2017 approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited, a wholly owned subsidiary of the company with the company with effect from 1 April 2017.The Board of Directors of Dr. Lal PathLabs at its meeting held on 7 August 2017 approved acquisition of 70% stake in Dr. Lal Path Labs Bangladesh (Pvt) Limited (DLPLB) from existing shareholders. Prior to investment in the company by Dr. Lal PathLabs, DLPLB shall be acquiring the running diagnostic business of a sole-proprietorship firm in Dhaka, Bangladesh. On 12 December 2017, Dr. Lal PathLabs announced that the Board of Directors of the company's subsidiary Paliwal Diagnostics Private Limited, at its meeting held on 12 December 2017 approved acquisition of a proprietary concern viz. Satya Pathology and Diagnostic Centre (SPDC) based out of Kanpur. SPDC clocked turnover of Rs 1.46 crore in FY 2017.Dr. Lal PathLabs' Kolkata Reference Lab started testing of samples in early January 2018. The World-class Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring international